GlassScriptPhysician profile
Christy Harrell Evans
NPI 1336560903
$3,357.96
in general payments reported to CMS, 2019-2025
28 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $260 · 2023: $717 · 2024: $1,422 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $400.57 | 2022-2025 | Omnipod |
| Lilly USA, LLC | $395.16 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $301.76 | 2023-2025 | Freestyle Libre 3 |
| Merz North America, INC. | $277.59 | 2023-2024 | Xeomin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.45 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $247.87 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $239.86 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Cequr Corporation | $212.08 | 2022-2025 | Cequr Simplicity |
| Novo Nordisk INC | $168.82 | 2023-2025 | Rybelsus, Ozempic, Saxenda |
| Beta Bionics, INC. | $161.06 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $147.61 | 2021-2025 | |
| Corcept Therapeutics | $72.90 | 2022-2024 | Korlym |
| Tandem Diabetes Care, INC. | $59.15 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $54.90 | 2023-2024 | Senza |
| Bayer Healthcare Pharmaceuticals INC. | $52.40 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.20 | 2023-2024 | Repatha |
| Sanofi-Aventis U.S. LLC | $39.25 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $35.19 | 2021 | |
| Ascensia Diabetes Care US INC. | $19.71 | 2023 | |
| Esperion Therapeutics, INC. | $18.40 | 2024 | Nexletol |
| Zealand Pharma US, INC. | $17.65 | 2022 | |
| Ascendis Pharma Endocrinology INC | $17.56 | 2024 | |
| Intra-Sana Laboratories | $16.49 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Glaxosmithkline, LLC. | $16.32 | 2025 | Shingrix, Arexvy, Penmenvy |
| Recordati_rare_diseases_inc. | $16.12 | 2024 | Signifor Lar, Isturisa |
| Medtronic, INC. | $14.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2024 | Farxiga |
| Chiesi USA, INC. | $13.16 | 2024 | Myalept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.